Evaluation of the Relative Bioavailability and Food Effect of AGMB-129 in Healthy Participants with Fibrostenotic Crohn’s Disease

The primary objective of this study is to evaluate the **relative bioavailability** of AGMB-129 in healthy participants. This is clinically relevant as understanding the bioavailability of a drug is crucial for determining the appropriate dosage and ensuring therapeutic efficacy. The study also aims to assess the effect of food on the bioavailability of AGMB-129, which is important for optimizing administration guidelines and improving patient outcomes in the management of **Fibrostenotic Crohn’s disease**.

The clinical trial involves participants diagnosed with **fibrostenotic Crohn's disease**. The study population includes both male and female subjects, with an age range classified under category code 3, which typically corresponds to adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and specific inclusion or exclusion criteria have not been disclosed. The sponsor has not provided information on the total number of participants involved in the study.

The clinical trial is designed to evaluate the **relative bioavailability** and the effect of food on AGMB-129 in healthy participants. This study is a Phase 3 trial, which is a critical stage in the clinical research process, focusing on the assessment of the drug's efficacy and monitoring of adverse reactions in a larger participant group. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias and enhancing the reliability of the results. The estimated recruitment start date is March 12, 2024, with an anticipated end date of April 23, 2024, indicating a relatively short trial duration.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on specific criteria. This initial visit will involve a comprehensive assessment to ensure participants meet the necessary health standards for inclusion in the trial. Following the screening, participants will be randomly assigned to either the treatment or control group. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the drug's effects, and collect data on any adverse events. These visits are crucial for maintaining participant safety and ensuring the integrity of the data collected. The trial will conclude with an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on the study's outcomes.

The expected length of participant involvement is approximately six weeks, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. These measures are in place to protect the well-being of the participants and maintain the ethical standards of the clinical trial. The study focuses on **fibrostenotic Crohn's disease**, a condition characterized by the narrowing of the intestines due to inflammation and fibrosis, although the trial itself involves healthy participants to assess the drug's bioavailability and food interaction.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. The absence of these details precludes a comprehensive description of the treatment regimen, dosing schedules, or participant compliance monitoring. Consequently, the trial's treatment protocol remains unspecified based on the provided data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on March 12, 2024, with an estimated end date of April 23, 2024. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The trial's primary focus is to evaluate the treatment's impact on the specified medical condition, utilizing scientifically validated tools and methodologies appropriate for a Phase 3 trial. The results will contribute to understanding the treatment's potential benefits and inform future clinical and regulatory decisions.